Periprocedural anticoagulant & antiplatelet management
Bridging decisions · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Managing antithrombotics around procedures balances thromboembolic risk against procedural bleeding. Most patients on DOACs do not need bridging, while a minority on warfarin with high thrombotic risk do; decisions are individualised by drug, renal function and bleeding risk.
Red flags
- Mechanical mitral valve (high thrombotic risk)
- Thromboembolic event within the preceding 3 months
- Recent coronary stent within the DAPT window
- Major bleeding during or after the procedure
- Antiphospholipid syndrome with prior thrombosis
Assessment
Differential diagnosis
- Atrial fibrillation on anticoagulation
- Mechanical heart valve
- Recent venous thromboembolism
- Recent coronary stent on DAPT
- Antiphospholipid syndrome
- Prior thromboembolism on warfarin
Investigations
- Renal function (to time DOAC interruption)
- INR for warfarin patients
- FBC for baseline haemoglobin/platelets
- Assessment of procedural bleeding risk
- Review of indication and thrombotic risk
- Liver function where relevant
Management
- Determine whether the procedure can proceed without stopping anticoagulation (minor/low-bleed procedures)
- Classify the patient's thrombotic risk and procedural bleeding risk
- For DOACs, stop based on drug, renal function and bleeding risk (commonly 24-48 h before)
- Do not routinely bridge DOAC patients — their offset is predictable
- For warfarin, stop ~5 days before and check INR before the procedure
- Bridge warfarin with LMWH only in high-thrombotic-risk patients (mechanical mitral valve, recent VTE/stroke)
- Avoid bridging low/moderate-risk AF patients on warfarin (increases bleeding)
- Plan the timing of restarting anticoagulation based on haemostasis and bleeding risk
- For recent coronary stents, delay elective surgery and continue aspirin where possible
- Coordinate antiplatelet interruption with the implanting cardiologist
- Give clear written restart instructions
- Document the plan and communicate with all teams
Drugs & doses
Resume DOAC (e.g. apixaban 5 mg PO BD) once haemostasis secured
Enoxaparin 1 mg/kg SC BD for high-risk warfarin bridging (last dose timed before surgery)
Warfarin restart on the evening of or day after the procedure
Continue aspirin 75-100 mg PO OD perioperatively in most stented patients
Reduced prophylactic LMWH dose for moderate-risk bridging where used
Disposition
Preoperative/anticoagulation clinic planning; cardiology input for mechanical valves, recent stents or complex thrombotic risk.
Complications & pitfalls
- Perioperative thromboembolism
- Procedural or postoperative bleeding
- Stent thrombosis from premature antiplatelet cessation
- Heparin-induced thrombocytopenia (with bridging)
- Delayed anticoagulation restart
Exam pearls
- BRIDGE trial showed no benefit and more bleeding from routine warfarin bridging in AF
- DOACs rarely need bridging — interruption timing depends on renal function
- Many minor procedures can continue on anticoagulation
- Resume full-dose anticoagulation cautiously after high-bleed-risk surgery
- Mechanical valves and very recent VTE are the main indications to bridge
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.